Quethera, a spin-out from the University of Cambridge, is a gene therapy company developing a novel treatment for glaucoma.

The company aims to deliver gene products for neuroprotectants and their receptors directly to the eye, which will provide long term neuroprotection to the retinal ganglion cells (RGC) in the eye, preventing their death and visual field loss. Retinal ganglion cell death is the ultimate conclusion in glaucoma and is what causes loss of sight in sufferers.